Follow-Up Findings in Multiple System Atrophy from [¹²³I]Ioflupane Single-Photon Emission Computed Tomography (SPECT): A Prospective Study.

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

BackgroundMultiple system atrophy (MSA) is subdivided into two types: MSA-P (parkinsonian) and MSA-C (cerebellar). Brain SPECT allows for the detection of nigrostriatal involvement, even in the early stages. To date, the scientific literature does not show a consensus on how to follow-up MSA, especially MSA-C. Our aim was to analyze the diagnostic effectiveness of repeat [123I]Ioflupane SPECT for the follow-up of MSA.MethodsA longitudinal observational study on 22 MSA patients (11 males and 11 females).ResultsSignificant changes were obtained in the quantitative SPECT assessments in the three Striatum/Occipital indices. The qualitative SPECT diagnosis did not show differences between the initial and evolving SPECT, but the neurologist's clinical suspicion did. Our results showed a brain deterioration of around 31% at 12 months, this being the optimal cut-off for differentiating a diseased subject (capable of solving diagnostic error rate). Previous imaging tests were inconclusive, as they showed less deterioration in the SPECT and quantitative assessments with respect to the group of confirmed patients. Repeated SPECT increased the diagnostic sensitivity (50% vs. 75%) and positive predictive value (72.73% vs. 77%). In addition, repeated SPECT proved decisive in the diagnosis of initial inconclusive cases.ConclusionRepeat SPECT at 12 months proves useful in the diagnosis and follow-up of MSA.

Related topics